載入...
Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up
Natalizumab inhibits the transmigration of immune cells across the blood-brain barrier thus inhibiting inflammation in the central nervous system. Generally, this blockade at the blood-brain barrier has significant influence on the circulating lymphocytes. Up to date, only short-term data on periphe...
Na minha lista:
| 發表在: | Front Neurol |
|---|---|
| Main Authors: | , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Frontiers Media S.A.
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6292961/ https://ncbi.nlm.nih.gov/pubmed/30581413 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fneur.2018.01071 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|